Back to search results

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Abroad (travel likely)RecruitingPHASE4

Conditions

Relapsing Remitting Multiple Sclerosis (RRMS)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Novartis Investigative Site, Calgary, Alberta, Canada

  • Novartis Investigative Site, Calgary, Alberta, Canada

  • Novartis Investigative Site, Edmonton, Alberta, Canada

  • Novartis Investigative Site, Burnaby, British Columbia, Canada

  • Novartis Investigative Site, Vancouver, British Columbia, Canada

  • Novartis Investigative Site, St. John's, Newfoundland and Labrador, Canada

  • Novartis Investigative Site, Halifax, Nova Scotia, Canada

  • Novartis Investigative Site, Halifax, Nova Scotia, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Sherbrooke, Quebec, Canada

Study leads

  • Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)